Vijaya Diagnostic Centre Ltd. (VIJAYA) AI Stock Analysis

• Market Cap: ₹101.85B
• Dividend Yield: 0.2%
• Average Volume (3M): 7.14K
• Price to Earnings (P/E): 67.2
• Beta (1Y): 0.51
• Revenue Growth: 16.71%
• EPS Growth: 13.92%
• Country: IN
• Employees: 2,053
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 4.20
• Shares Outstanding: 102,724,940
• 10 Day Avg. Volume: 16,300
• 30 Day Avg. Volume: 7,139
• PEG Ratio: 3.49
• Price to Book (P/B): 12.57
• Price to Sales (P/S): 14.68
• P/FCF Ratio: 77.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: ₹1,216.00 ▲(15.22% Upside)

Vijaya Diagnostic Centre Ltd. demonstrates strong financial performance with robust revenue growth and profitability, which significantly contributes to its overall score. Technical analysis indicates positive momentum, though caution is advised due to a high RSI. The valuation is a concern with a high P/E ratio, suggesting potential overvaluation. The absence of earnings call and corporate events data did not impact the score.

Positive Factors

Revenue Growth

Sustained revenue growth indicates expanding market reach and increased demand for diagnostic services, supporting long-term business expansion.

Profitability Margins

High profitability margins reflect efficient operations and cost management, enhancing the company's ability to reinvest in growth and innovation.

Cash Flow Management

Strong cash flow management ensures sufficient liquidity for operational needs and strategic investments, supporting sustainable growth.

Negative Factors

High Valuation Concerns

A high valuation may limit future investment returns and increase risk if growth expectations are not met, impacting investor sentiment.

Potential Bearish Trends

Persistent bearish trends could indicate market skepticism about the company's growth prospects, affecting long-term investor confidence.

Liability Management

While leverage is low, further reduction in liabilities could enhance financial stability and provide greater flexibility for future investments.

Vijaya Diagnostic Centre Ltd. Business Overview & Revenue Model

Company Description

Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. It offers laboratory services, including clinical biochemistry, haematology and immune-haematology, clinical pathology, histopathology and cytopathology, microbiology, serology, cytogenetics, and molecular pathology; radiology and imaging services comprising magnetic resonance imaging, multi slice CT, CBCT (3D dental), mammography, DEXA/bone densitometry, ultrasound/color doppler, nuclear medicine and PET/CT, and digital X-ray; and cardiology, neurology, and gastroenterology services. The company also provides health checkups and home sample collection services. It has a network, which consists of 80 diagnostic center and 11 reference laboratories across 13 cities and towns in the states of Telangana and Andhra Pradesh, and in the National Capital Region and Kolkata. The company was founded in 1981 and is based in Hyderabad, India.

How the Company Makes Money

Vijaya Diagnostic Centre Ltd. generates revenue primarily through the provision of diagnostic services, which include laboratory tests, imaging services, and health check-up packages. The company charges fees for each test and service provided, contributing to its core revenue stream. Additionally, VIJAYA may engage in partnerships with hospitals, clinics, and insurance companies, which can enhance patient referrals and increase service demand. Revenue is further bolstered by preventive health check-up packages, which attract a broad demographic seeking proactive healthcare solutions. Seasonal trends and public health initiatives can also influence earnings, as increased awareness of health issues often leads to a rise in diagnostic testing.

Vijaya Diagnostic Centre Ltd. Financial Statement Overview

Summary

Vijaya Diagnostic Centre Ltd. exhibits strong financial performance with significant revenue growth, high profitability margins, and efficient cash flow management. The balance sheet reflects low leverage and solid equity standing, while cash flows show positive trends and solid operational cash generation. The company is well-positioned for continued growth, though maintaining low liabilities would further enhance financial stability.

Income Statement

The company demonstrates strong revenue growth with a 24.38% increase from 2024 to 2025. Gross profit margin is impressive at 87.58%, and net profit margin has improved to 21.00%. EBIT and EBITDA margins are robust at 71.10% and 40.10%, respectively, indicating efficient operations and cost management. Overall, the income statement reflects positive growth and profitability trends.

Balance Sheet

The balance sheet shows a solid equity base with a debt-to-equity ratio of 0.40, which indicates low leverage. The company maintains a good equity ratio of 62.47%, highlighting financial stability. Return on equity is strong at 17.98%, reflecting effective use of equity to generate profits. The balance sheet is healthy, though there is room for improvement in reducing liabilities further.

Cash Flow

Operating cash flow is strong, translating into a high operating cash flow to net income ratio of 1.57. Free cash flow shows positive growth, increasing by 35.20% from the previous period. The free cash flow to net income ratio of 0.90 indicates effective cash management and ability to generate cash from operations. Overall, cash flow is robust, supporting the company's growth and operational needs.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	7.13B	6.81B	5.48B	4.59B	4.62B	3.76B
Gross Profit	6.26B	5.97B	4.61B	2.25B	3.91B	3.19B
EBITDA	3.01B	2.73B	2.39B	1.96B	2.16B	1.77B
Net Income	1.50B	1.43B	1.19B	846.32M	1.10B	844.78M
Balance Sheet
Total Assets	0.00	12.74B	9.83B	8.53B	7.13B	5.41B
Cash, Cash Equivalents and Short-Term Investments	2.33B	2.33B	1.85B	2.55B	2.25B	2.20B
Total Debt	0.00	3.20B	2.59B	2.48B	1.83B	1.41B
Total Liabilities	-7.99B	4.74B	3.23B	3.07B	2.44B	1.82B
Stockholders Equity	7.99B	7.96B	6.57B	5.45B	4.68B	3.59B
Cash Flow
Free Cash Flow	0.00	1.29B	953.37M	397.69M	356.50M	975.07M
Operating Cash Flow	0.00	2.24B	1.83B	1.65B	1.58B	1.30B
Investing Cash Flow	0.00	-1.82B	-1.42B	-1.10B	-1.23B	-1.30B
Financing Cash Flow	0.00	-520.48M	-445.50M	-419.12M	-305.72M	-487.69M

Vijaya Diagnostic Centre Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1055.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIJAYA, the sentiment is Negative. The current price of 1055.4 is above the 20-day moving average (MA) of 1019.52, above the 50-day MA of 1018.69, and above the 200-day MA of 1010.15, indicating a bearish trend. The MACD of 3.26 indicates Positive momentum. The RSI at 40.76 is Neutral, neither overbought nor oversold. The STOCH value of 14.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIJAYA.

Vijaya Diagnostic Centre Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIJAYA	75 Outperform	₹101.85B	67.23	―	0.20%	16.71%	13.92%
HCG	67 Neutral	₹90.12B	252.67	―	―	17.58%	-38.20%
KRSNAA	62 Neutral	₹23.70B	27.95	―	0.38%	11.51%	21.56%
METROPOLIS	61 Neutral	₹99.74B	62.88	―	0.21%	15.41%	5.93%
UNICHEMLAB	54 Neutral	₹29.22B	33.03	―	―	25.42%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Vijaya Diagnostic Centre Ltd. Corporate Events

Vijaya Diagnostic Centre Releases Q2 FY ’26 Earnings Call Transcript

Vijaya Diagnostic Centre Ltd. announced the transcript of its earnings conference call for the second quarter and half-year ending September 30, 2025. This announcement follows the release of the company’s unaudited financial results, providing insights into its financial performance and strategic direction. The conference call featured key management personnel discussing the company’s operations, which could have implications for stakeholders and market positioning.

Vijaya Diagnostic Centre Ensures Regulatory Compliance with SEBI Certificate Submission

Vijaya Diagnostic Centre Ltd. has submitted a certificate in compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming the details of securities dematerialized and rematerialized during the quarter ending September 30, 2025. This compliance ensures transparency and adherence to regulatory requirements, potentially strengthening the company’s credibility and trust with stakeholders.